Novo Nordisk Outlines Ambitious 2030 Strategy Amid Share Price Decline
At its Capital Markets Day on September 21, Novo Nordisk (ticker: NOVO-B.CO) outlined a five-year strategy aimed at launching more than five blockbuster drugs by 2030 and achieving over DKr150bn ($23bn) in sales. The plan includes expanding beyond semaglutide-based products like Wegovy and Ozempic, which generated $7.8bn globally in Q2 but lag behind Eli Lilly's tirzepatide with near-$15bn in the same period. A key development was a positive Phase III trial for CagriSema, Novo’s next-generation GLP-1RA, showing superior weight loss compared to lower-dose tirzepatide. However, investors remained cautious as shares fell 5% on September 21 and have dropped over 70% since mid-2024. Analysts from Citi noted the company's growth targets were in line with expectations but did not significantly alter their cautious outlook. The strategy also includes expanding capacity for its oral Wegovy, approved in December 2025, aiming to serve ten times more patients within five years. Novo has diversified through acquisitions like Akero Therapeutics and partnerships such as one worth up to $1.4bn with Orbis Medicines.
Topics: blockbuster drugs capital markets day drug pipeline GLP-1RA obesity treatments